CD7 was previously described to be aberrantly expressed on CD34+ cells in JMML31, and there are both pre-clinical data32 and early-phase clinical trials (NCT05377827) of CD7CARTs for patients with T-ALL or AML. Here, CD7 is linked to acute myeloid leukemia.